Lapatinib Ditosylate - CAS 388082-77-7
Catalog number: 388082-77-7
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C29H26ClFN4O4S.2C7H8O3S
Molecular Weight:
925.46
COA:
Inquire
Targets:
EGFR
Description:
Lapatinib is a synthetic, orally-active quinazoline with potential antineoplastic activity. Lapatinib reversibly blocks phosphorylation of the epidermal growth factor receptor (EGFR), ErbB2, and the Erk-1 and-2 and AKT kinases; it also inhibits cyclin D protein levels in human tumor cell lines and xenografts. EGFR and ErbB2 have been implicated in the growth of various tumor types.
Publictions citing BOC Sciences Products
  • >> More
Purity:
>98%
Synonyms:
GW-572016
MSDS:
Inquire
1.Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial.
Awada A1, Colomer R2, Inoue K3, Bondarenko I4, Badwe RA5, Demetriou G6, Lee SC7, Mehta AO8, Kim SB9, Bachelot T10, Goswami C11, Deo S12, Bose R13, Wong A14, Xu F14, Yao B14, Bryce R14, Carey LA15. JAMA Oncol. 2016 Apr 14. doi: 10.1001/jamaoncol.2016.0237. [Epub ahead of print]
Importance: Efficacious ERBB2 (formerly HER2 or HER2/neu)-directed treatments, in addition to trastuzumab and lapatinib, are needed.
2.Characterization of the binding of an anticancer drug, lapatinib to human serum albumin.
Kabir MZ1, Mukarram AK2, Mohamad SB3, Alias Z1, Tayyab S4. J Photochem Photobiol B. 2016 Apr 13;160:229-239. doi: 10.1016/j.jphotobiol.2016.04.005. [Epub ahead of print]
Interaction of a promising anticancer drug, lapatinib (LAP) with the major transport protein in human blood circulation, human serum albumin (HSA) was investigated using fluorescence and circular dichroism (CD) spectroscopy as well as molecular docking analysis. LAP-HSA complex formation was evident from the involvement of static quenching mechanism, as revealed by the fluorescence quenching data analysis. The binding constant, Ka value in the range of 1.49-1.01×105M-1, obtained at three different temperatures was suggestive of the intermediate binding affinity between LAP and HSA. Thermodynamic analysis of the binding data (∆H=-9.75kJmol-1 and ∆S=+65.21Jmol-1K-1) suggested involvement of both hydrophobic interactions and hydrogen bonding in LAP-HSA interaction, which were in line with the molecular docking results. LAP binding to HSA led to the secondary and the tertiary structural alterations in the protein as evident from the far-UV and the near-UV CD spectral analysis, respectively.
3.Ridaforolimus improves the anti-tumor activity of dual HER2 blockade in uterine serous carcinoma in vivo models with HER2 gene amplification and PIK3CA mutation.
Hernandez SF1, Chisholm S2, Borger D3, Foster R4, Rueda BR4, Growdon WB5. Gynecol Oncol. 2016 Apr 1. pii: S0090-8258(16)30083-X. doi: 10.1016/j.ygyno.2016.03.027. [Epub ahead of print]
OBJECTIVE: Uterine serous carcinomas (USC) harbor simultaneous HER2 (ERBB2) over-expression and gain of function mutations in PIK3CA. These concurrent alterations may uncouple single agent anti-HER2 therapeutic efficacy making inhibition of the mammalian target of rapamycin (mTOR) a promising option to heighten anti-tumor response.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related EGFR Products


CAS 118409-57-7 AG-18

AG-18
(CAS: 118409-57-7)

AG 18 (10 μM) inhibits EGF-induced proliferation of GH3 cells.

CAS 1353550-13-6 Olmutinib

Olmutinib
(CAS: 1353550-13-6)

Olmutinib, also called as HM61713 and BI-1482694, is an orally available, mutant-selective third-generation epidermal growth factor receptor tyrosine kinase inh...

CAS 231277-92-2 Lapatinib

Lapatinib
(CAS: 231277-92-2)

Lapatinib, used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM, respectively.

CAS 388082-77-7 Lapatinib Ditosylate

Lapatinib Ditosylate
(CAS: 388082-77-7)

Lapatinib is a synthetic, orally-active quinazoline with potential antineoplastic activity. Lapatinib reversibly blocks phosphorylation of the epidermal growth ...

Tarloxotinib bromide
(CAS: 1636180-98-7)

Tarloxotinib bromide, a pyridopyrimidine derivative, has been found to be a EGFR tyrosine kinase inhibitor precursor and could probably be effective in antineop...

Naquotinib mesylate
(CAS: 1448237-05-5)

Naquotinib is irreversible, third-generation, epidermal growth factor receptor (EGFR) inhibitor with IC50 value of 70 nM for NCI-H1650 cell growth. It can coval...

CAS 183322-45-4 PD153035 HCl

PD153035 HCl
(CAS: 183322-45-4)

PD153035 is a potent and specific inhibitor of EGFR with Ki and IC50 of 5.2 pM and 29 pM; little effect noted against PGDFR, FGFR, CSF-1, InsR and Src.

CAS 1092364-38-9 Poziotinib

Poziotinib
(CAS: 1092364-38-9)

Poziotinib, also known as HM781-36B and NOV120101, is an orally bioavailable, quinazoline-based pan epidermal growth factor receptor (EGFR or HER) inhibitor wit...

CAS 610798-31-7 Icotinib

Icotinib
(CAS: 610798-31-7)

Icotinib Hydrochloride (BPI-2009H), or Icotinib, is a highly selective, first generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI).

CAS 153436-54-5 PD-153035

PD-153035
(CAS: 153436-54-5)

PD153035 is a ATP-competitive EGFR inhibitor with an IC50 and Ki of 25 and 6 pM. PD153035 effectively blocks the enhancement of mitogenesis, induction of early ...

CAS 714971-09-2 AC480

AC480
(CAS: 714971-09-2)

AC480, also known as BMS-599626, is an orally bioavailable inhibitor of the HER1, HER2 and HER4 tyrosine kinases (IC50 =22, 32 and 190 nM, respectively) with po...

CAS 1375465-09-0 CNX-2006

CNX-2006
(CAS: 1375465-09-0)

CNX-2006 is a potent, mutant-selective EGFR inhibitor with excellent in vitro activity in cells with activating EGFR mutations, as well as in cells harbouring t...

AZ5104
(CAS: 1421373-98-9)

AZ5104, the demethylated metabolite of AZD-9291, is a potent EGFR inhibitor with IC50 of

Anlotinib
(CAS: 1058156-90-3)

Anlotibib is a multi-targetes kinase inhibitor of receptor tyrosine and could effectively resist the formation of new angiogenesis and is under Phase III trail ...

CAS 451493-31-5 AV-412 Tosylate

AV-412 Tosylate
(CAS: 451493-31-5)

AV-412 is a dual EGFR/ErbB2 kinase inhibitor. It completely inhibits the tumor growth of both H1650 and H1975 xenografts in nude mice. It is proved that AV-412 ...

CAS 859853-30-8 BMS-6690514

BMS-6690514
(CAS: 859853-30-8)

BMS-690514 is a potent inhibitor of human epidermal growth factor receptor (HER) 1 (EGFR), 2, and 4, and vascular endothelial growth factor receptors (VEGFR) 1-...

CAS 248594-19-6 Erlotinib mesylate

Erlotinib mesylate
(CAS: 248594-19-6)

Erlotinib is an EGFR inhibitor. The drug follows Iressa (gefitinib), which was the first drug of this type. Erlotinib specifically targets the epidermal growth ...

α- epidermal growth factor, human
(CAS: 62253-63-8)

Recombinant human epidermal growth factor has the same structure as the human epidermal growth factor. EGF binds to epidermal growth factor receptor (EGFR) and ...

CAS 184475-35-2 Gefitinib

Gefitinib
(CAS: 184475-35-2)

Gefitinib effectively inhibits all tyrosine phosphorylation sites on EGFR in both the high and low-EGFR-expressing cell lines including NR6, NR6M and NR6W cell ...

SKLB-1028
(CAS: 1350544-93-2)

SKLB1028 is a novel Bcr-abl tyrosine kinase inhibitor, Epidermal growth factor inhibitor and Fms-like tyrosine kinase 3 inhibitor originated by CSPC Ouyi Pharma...

Chemical Structure

CAS 388082-77-7 Lapatinib Ditosylate

Quick Inquiry

Verification code

Featured Items